A New Measure of Child-Reported Symptomatic Toxicities of Cancer Treatment: Introducing Pediatric PRO-CTCAE®

Date: Thursday, March 26, 2020
Time: 2:00 – 3:00 pm EST


NCI’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) was developed to capture symptomatic toxicity by patient self-report in cancer clinical trials. A pediatric version of PRO-CTCAE (Ped-PRO-CTCAE®) is now available to enable self-reporting of symptomatic adverse events by children and adolescents.

In this webinar speakers and discussants

  • Describe the design and psychometric testing of Ped-PRO-CTCAE®
  • Demonstrate the creation of customized PRO-CTCAE® surveys
  • Highlight the value of this new measure for pediatric oncology trials

Intended Audience

Extramural investigators at junior, mid, and senior levels.

Suggested Readings

  • Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Am Soc Clin Oncol Educ Book 2016;35:67-73. doi: 10.14694/EDBK_159514
  • Reeve BB et al. Pediatr Blood and Cancer 2017;64(3):1-7. DOI: 10.1002/pbc.26261.
  • Reeve BB et al. JNCI. Published online first. https://doi.org/10.1093/jnci/djaa016External Web Site Policy


Pamela S. Hinds

Pamela S. Hinds, PhD, RN, FAAN
Children's National Hospital

Molly McFatrich

Molly McFatrich, MPH
Duke University School of Medicine

Bryce B. Reeve

Bryce B. Reeve, PhD
Duke University School of Medicine


David R. Freyer

David R. Freyer, DO, MS
Children's Hospital Los Angeles
USC Norris Comprehensive Cancer Center

Gregory H. Reaman

Gregory H. Reaman, MD
U.S. Food & Drug Administration

Douglas S. Hawkins, MD
Seattle Children's Hospital


Sandra A. Mitchell

Sandra A. Mitchell, PhD, CRNP, FAAN
National Cancer Institute

This webinar will be archived on the HDRP Events webpage.

Last Updated: 19 Apr, 2024